If successful, a new remyelinating antibody called rHIgM22 may help reverse nerve damage caused by MS. In a collaboration between the Mayo Clinic and Acorda Therapeutics, Inc., a “first-in-human” trial of the drug rHIgM22 to repair nerve damage caused by multiple sclerosis (MS) is currently recruiting volunteers.
Earlier animal studies of rHIgM22 showed improvements in motor activity, meaning a possible reversal of disability. If successful, this could be a groundbreaking achievement, particularly for those with progressive forms of MS, for which there are no treatments currently available. Read more about this drug trial here.